<i>In vitro</i> assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)

Chavarin, Patricia; Cognasse, Fabrice; Argaud, C.; Vidal, M.; Pütter, Carolin; Boussoulade, F.; Ripaud, C.; Acquart, Sophie; Lin, Lily; Garraud, Olivier

doi:10.1111/j.1423-0410.2010.01389.x

Cited by 25 publications

(31 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Platelets are stored in a mixture of plasma and additive solution with citrate as anticoagulant, which is quite different from their physiological environment. Certain methods require preliminary reconstitution of whole blood, or the addition of electrolytes (i.e., Ca ++ and Mg ++ ) [40,41]. More importantly, in vitro test results are often unable to predict platelet function after transfusion, because a certain degree of functional recovery may occur [42,43].…”

Section: Functional and Biochemical Studiesmentioning

confidence: 99%

The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

et al. 2014

View full text Add to dashboard Cite

Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity.

show abstract

Section: Functional and Biochemical Studiesmentioning

confidence: 99%

The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

et al. 2014

View full text Add to dashboard Cite

show abstract

“…These factors include a large number of microparticles; oxygenated moieties of membrane lipids; inflammatory mediators such as histamine, serotonin, and ADP/ATP; and biological response modifiers (BRMs) that themselves comprise cytokines, chemokines, growth factors, inhibitory factors, and related molecules [2], [6]–[11]. There is further evidence that all pro-inflammatory factors increase over time (at 22±2°C, in general up to 5 days and occasionally up to 7 days) in stored PCs, which constitute the transfusion inventory issued to patients in need [12], [13]. BRMs in particular are principally shed from the platelet membranes or secreted from docks [14], [15].…”

Section: Introductionmentioning

confidence: 99%

A Computerized Prediction Model of Hazardous Inflammatory Platelet Transfusion Outcomes

et al. 2014

View full text Add to dashboard Cite

BackgroundPlatelet component (PC) transfusion leads occasionally to inflammatory hazards. Certain BRMs that are secreted by the platelets themselves during storage may have some responsibility.Methodology/Principal FindingsFirst, we identified non-stochastic arrangements of platelet-secreted BRMs in platelet components that led to acute transfusion reactions (ATRs). These data provide formal clinical evidence that platelets generate secretion profiles under both sterile activation and pathological conditions. We next aimed to predict the risk of hazardous outcomes by establishing statistical models based on the associations of BRMs within the incriminated platelet components and using decision trees. We investigated a large (n = 65) series of ATRs after platelet component transfusions reported through a very homogenous system at one university hospital. Herein, we used a combination of clinical observations, ex vivo and in vitro investigations, and mathematical modeling systems. We calculated the statistical association of a large variety (n = 17) of cytokines, chemokines, and physiologically likely factors with acute inflammatory potential in patients presenting with severe hazards. We then generated an accident prediction model that proved to be dependent on the level (amount) of a given cytokine-like platelet product within the indicated component, e.g., soluble CD40-ligand (>289.5 pg/109 platelets), or the presence of another secreted factor (IL-13, >0). We further modeled the risk of the patient presenting either a febrile non-hemolytic transfusion reaction or an atypical allergic transfusion reaction, depending on the amount of the chemokine MIP-1α (<20.4 or >20.4 pg/109 platelets, respectively).Conclusions/SignificanceThis allows the modeling of a policy of risk prevention for severe inflammatory outcomes in PC transfusion.

show abstract

“…Currently, several technologies are available that allow for pathogen reduction in platelets and plasma using ultraviolet (UV)C, riboflavin and broadband UV, or amotosalen and UVA . However, development of a robust PRT for RBCs has been problematic .…”

mentioning

confidence: 99%

Red blood cell in vitro quality and function is maintained after S‐303 pathogen inactivation treatment

et al. 2014

View full text Add to dashboard Cite

show abstract

In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)

Abstract: Additional metabolic and activation assessments of the treated platelets confirmed the previously reported superiority of PAS-IIIM over PAS-III, but extended it to the INTERCEPT™ process.

Cited by 25 publications

References 6 publications

The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

A Computerized Prediction Model of Hazardous Inflammatory Platelet Transfusion Outcomes

Red blood cell in vitro quality and function is maintained after S‐303 pathogen inactivation treatment

Contact Info

Product

Resources

About